| Literature DB >> 31817084 |
Ming-Shun Wu1,2,3, Levent Bless B Aquino4, Marjette Ylreb U Barbaza4, Chieh-Lun Hsieh5, Kathlia A De Castro-Cruz4, Ling-Ling Yang6,7, Po-Wei Tsai8.
Abstract
The use of foodstuff as natural medicines has already been established through studies demonstrating the pharmacological activities that they exhibit. Knowing the nutritional and pharmacological significance of foods enables the understanding of their role against several diseases. Among the foods that can potentially be considered as medicine, is sesame or Sesamum indicum L., which is part of the Pedaliaceae family and is composed of its lignans such as sesamin, sesamol, sesaminol and sesamolin. Its lignans have been widely studied and are known to possess antiaging, anticancer, antidiabetes, anti-inflammatory and antioxidant properties. Modern chronic diseases, which can transform into clinical diseases, are potential targets of these lignans. The prime example of chronic diseases is rheumatic inflammatory diseases, which affect the support structures and the organs of the body and can also develop into malignancies. In line with this, studies emphasizing the anti-inflammatory and anticancer activities of sesame have been discussed in this review.Entities:
Keywords: Sesamum indicum L.; anti-cancer; anti-inflammatory; sesame extracts; sesame oil
Mesh:
Substances:
Year: 2019 PMID: 31817084 PMCID: PMC6943436 DOI: 10.3390/molecules24244426
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical Structures of Sesamum indicum L. lignans.
In vivo models for the anti-inflammatory effects of sesame lignans.
| Compound | Inflammatory Disease/Disorder | Rat Model | References |
|---|---|---|---|
| Sesamin | Depression | Chronic unpredictable mild stress (CUMS) rat model | [ |
| Ischemic brain stroke | Middle cerebral artery occlusion (MCAO) rat model | [ | |
| Parkinson’s disease | 6-hydroxydopamine (6-OHDA) rat model | [ | |
| Osteoarthritis | Papain-induced osteoarthritis rat model | [ | |
| Hepatic steatosis | High-fat diet rat model | [ | |
| Fulminant hepatic failure | [ | ||
| Acute hepatic injury | Lead-induced acute hepatic injury rat model | [ | |
| Diabetic Retinopathy | Streptozotocin (STZ) induced rat model | [ | |
| LPS-induced leukotrienes generation | ad libitum semi-synthetic diet rat model | [ | |
| Sesamol | Ulcerative colitis | Dinitrochlorobenzene (DNCB)—induced rat model | [ |
| Gastric ulceration | Aspirin-induced gastric mucosal rat model | [ | |
| Acute lung injury | Endotoxin-induced acute pulmonary inflammation rat model | [ | |
| Sesaminol | Alzheimer’s disease | senescence-accelerated mouse-prone 8 (SAMP8) model | [ |
| Sesame Oil | Nonalcoholic steatohepatitis | Methionine-choline deficient (MCD) diet rat model | [ |
| Hepatic steatosis | High-fat diet-fed rat model | [ | |
| Cardiac hypertrophy | Deoxycorticosterone/salt (DOCA/salt)-induced hypertension uninephrectomized rat model | [ |
In vitro models for the anti-inflammatory effects of sesame lignans.
| Compound | Mechanism of Action | Cell Line | References |
|---|---|---|---|
| Sesamin | Inhibition of LPS-induced TLR4 expression | BV-2 microglial cell | [ |
| Inhibition of LPS-induced IL-6 mRNA and protein | BV-2 microglial cell | [ | |
| Inhibition of HO-1 protein ubiquitination | RAW 264.7 murine macrophage cells | [ | |
| Activation of Nrf2/ARE | PC12 rat pheochromocytoma cells. | [ | |
| Inhibition of IL-1β-stimulated human osteoarthritis chondrocytes. | Primary chondrocytes | [ | |
| Inhibition of oxidized low-density lipoprotein (oxLDL)-induced endothelial dysfunction | Human umbilical vein endothelial cells (HUVECs) | [ | |
| Episesamin and Sesamin metabolites | Activation of Nrf2/ARE | PC12 rat pheochromocytoma cells. | [ |
| Sesamin Catechol Glucuronides | Inhibition of LPS-induced NO production | J774.1 mouse macrophage-like cells | [ |
| Sesamol | Inhibition of MMPs expression | SW1353 human chondrosarcoma cells | [ |
| Inhibition of inflammatory LOX | Soy LOX-1 enzyme model | [ | |
| Sesaminol Triglucoside | Inhibition of IL-6 and TNF-α | RAW 264.7 murine macrophage cells | [ |
| Sesamolin | Reduce the activation of p38 MAPK | BV-2 microglial cell | [ |
In vitro/in vivo applications of different extracts from different sesame components.
| Sesame Component | Mode of Extraction/Solvent | In vitro/In vivo | References |
|---|---|---|---|
| Sesame Oil | Aqueous extract | RAW 264.7 macrophage cell line | [ |
| Black Sesame Seeds | Ethanol extract | Fructose-induced NAFLD rat model | [ |
| Black Sesame Seeds | Ethanol extract | Freund’s complete adjuvant (FCA)-induced arthritis rat model | [ |
| Black Sesame Seeds | CO2 supercritical fluid extraction | Endothelin-1-induced focal ischemia rat model | [ |
| Sesame Coat | Ethanol extract | RAW 264.7 macrophage cell line | [ |
Sesame lignans against different types of cancer and the mechanisms of action.
| Compound | Cancer Type | Cell Line | Mechanism of Action | Reference |
|---|---|---|---|---|
| Sesame Oil | Skin Cancer | |||
| human malignant melanoma | SK-MEL | - | [ | |
| two-stage mouse skin carcinogenesis | in vivo | protection against TPA tumor promotion | [ | |
| Sesame Extract | Liver Cancer | |||
| human hepatocellular carcinoma | HepG2 | - | [ | |
| Sesamin | Blood Cancer | |||
| chronic myeloid leukemia | K562 | inhibition of TNF-induced NF-κB activation | [ | |
| myeloma | U266 | inhibition of TNF-induced NF-κB activation | [ | |
| Breast Cancer | MCF-7 | induction of G1 cell cycle arrest; down-regulation of Cyclin D1 protein | [ | |
| MCF-7 | inhibition of macrophage-induced VEGF and MMP-9 mRNA expressions | [ | ||
| MDA-MB-231 | inhibition of TNF-induced NF-κB activation | [ | ||
| MCF-7 | induction of G1 cell cycle arrest and reduction of protein expression levels | [ | ||
| MCF-7 | down regulation of growth factor receptors EGFR, HER2, and pMAPK expression | [ | ||
| Cervical Cancer | HeLa | favored apoptosis through the increase of Bax/Bcl-2 ratio; ER stress-mediated apoptosis by IRE1α/JNK pathway | [ | |
| Colon Cancer | ||||
| colon carcinoma | HCT116 | inhibition of TNF-induced NF-κB activation | [ | |
| Liver Cancer | ||||
| human hepatocellular carcinoma | HepG2 | suppression of the STAT3 signaling pathway | [ | |
| Lung Cancer | ||||
| human lung adenocarcinoma | H1299 | inhibition of TNF-induced NF-κB activation | [ | |
| Pancreatic cancer | MiaPaCa-2 | inhibition of TNF-induced NF-κB activation | [ | |
| Prostate Cancer | PC-3 | degradation of γ-tocopherol metabolism | [ | |
| DU145 | inhibition of TNF-induced NF-κB activation | [ | ||
| Skin Cancer | ||||
| malignant melanoma | SK-MEL2 | absorption of ultraviolet in the UV range and inhibition of mushroom and cellular tyrosinase | [ | |
| Sesaminol | Blood Cancer | |||
| lymphoid leukemia | Molt 4B | DNA fragmentation leading to apoptosis | [ | |
| Breast Cancer | MCF-7 | Reduction of cyclin D1 expression by binding to ANT2 protein | [ | |
| Colon Cancer | ||||
| colon carcinoma | RKO | Reduction of cyclin D1 expression by binding to ANT2 protein | [ | |
| Lung Cancer | ||||
| lung adenocarcinoma | A549 | Reduction of cyclin D1 expression by binding to ANT2 protein | [ | |
| Skin Cancer | ||||
| melanoma | SK-MEL-28 | Reduction of cyclin D1 expression by binding to ANT2 protein | [ | |
| Sesamol | Blood Cancer | |||
| acute myeloid leukemia | HL-60 | DNA fragmentation leading to apoptosis | [ | |
| chronic myeloid leukemia | K562 | oxidation to tetramer; increased caspases activity leading to DNA damage | [ | |
| lymphoid leukemia | Molt 4B | DNA fragmentation leading to apoptosis | [ | |
| Breast Cancer | MCF-7 | growth inhibition and apoptosis in S and G2/M phases | [ | |
| Colon Cancer | ||||
| colon adenocarcinoma | DLD-1 | suppression of cyclooxygenase-2 transcriptional activity | [ | |
| colon carcinoma | HCT116 | subG1 phase cell cycle arrest causing cell death | [ | |
| Liver Cancer | ||||
| human hepatocellular carcinoma | HepG2 | induced apoptosis and necrosis via DNA fragmentation and | [ | |
| induced apoptosis via suppression of autophagy | ||||
| Lung Cancer | ||||
| lung adenocarcinoma | SK-LU-1 | increased activity of caspase 3 leading to DNA damage | [ | |
| Skin Cancer | ||||
| human malignant melanoma | SK-MEL2 | absorption of ultraviolet in the UV range and inhibition of mushroom and cellular tyrosinase | [ | |
| mouse melanoma | B16F10 | inhibition of monophenolase and diphenolase activities and promotion of apoptosis | [ | |
| two-stage mouse skin carcinogenesis | in vivo | protection against TPA tumor promotion | [ | |
| Others | ||||
| Mouse Leydig tumor | MA-10 | increased activity of caspase 3 leading to DNA damage at subG1 phase | [ | |
| Sesamolin | Blood Cancer | |||
| Burkitt’s lymphoma | Raji | enhancement of NK cell lysis activity via escalated NKG2D ligand expression | [ | |
| Prostate Cancer | PC-3 | degradation of γ-tocopherol metabolism | [ | |
| Skin Cancer | ||||
| human malignant melanoma | SK-MEL2 | absorption of ultraviolet in the UV range and inhibition of mushroom and cellular tyrosinase | [ |
Figure 2Anti-inflammatory and anti-cancer activities of major sesame lignans.